Drug Interaction Report

Buprenorphine and Artemether: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Artemether

No brand names on record
+

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 633 documented Buprenorphine interactions, 601 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Theoretical Effects may be weaker Some uncertainty
The Bottom Line
Combining artemether/lumefantrine with buprenorphine may add to heart-rhythm (QT) risk and may lower buprenorphine's effect; avoid together if possible, and if both are needed your care team can monitor your ECG and adjust as needed.

Taking artemether (a malaria medicine) together with buprenorphine (used for pain or opioid treatment) can be a concern for two reasons. First, both drugs can affect your heart's rhythm in a way called QT prolongation, and combining them may add to that risk. Second, artemether can speed up how your body breaks down buprenorphine, which could make the buprenorphine work less well.

The good news is your care team can manage this. If you truly need both, they may check your heart with an ECG and watch how you're doing. Please don't stop or change either medicine on your own. Just talk with your pharmacist or doctor so they can guide you safely.

Two concerns:

  • Additive QT prolongation: both artemether (with lumefantrine) and buprenorphine can prolong the QT interval, raising arrhythmia (torsades) risk.
  • CYP3A4 induction: artemether/lumefantrine may induce CYP3A4, reducing exposure (AUC/Cmax) of buprenorphine, a CYP3A4 substrate, potentially lowering efficacy.

Evidence: theoretical. Onset: unspecified. Management: avoid coadministration where possible. If medically required, perform ECG monitoring and assess electrolytes. Note lumefantrine's long half-life (3 to 6 days), so caution persists after therapy ends. Buprenorphine dose may need individualization by the care team.

Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates

Interaction Deep Dive

The combined use of artemether/lumefantrine with CYP3A4 substrates that lengthen the QT interval should be avoided, since this pairing can decrease exposure to the CYP3A4 substrates and may heighten the likelihood of QT interval prolongation. Should coadministration of artemether/lumefantrine with a QT prolonging agent be clinically necessary, ECG monitoring is warranted. Furthermore, because lumefantrine has a long half-life (3 to 6 days), caution should be exercised when giving QT prolonging drugs even after artemether/lumefantrine treatment has been completed1.

Why it happens (mechanism)

Additive QT interval prolongation; induction of CYP3A4-mediated metabolism by artemether/lumefantrine

How to manage this interaction

What your care team may do:

  • Avoid using these two together when a safer option exists.
  • If both are truly needed, monitor your heart rhythm with an ECG and watch how well your buprenorphine is working.
  • Stay cautious even after finishing the malaria treatment, because lumefantrine stays in the body for several days (about 3 to 6).
  • Any buprenorphine dose change would be adjusted and individualized by your care team.

What you should do: Keep taking both as prescribed and let your pharmacist or doctor know you take them together, especially if you feel dizzy, faint, or notice a fluttering heartbeat.

Management is individual — confirm any change with your pharmacist or prescriber.

Common questions

Can I take Buprenorphine and Artemether together?

Combining artemether/lumefantrine with buprenorphine may add to heart-rhythm (QT) risk and may lower buprenorphine's effect; avoid together if possible, and if both are needed your care team can monitor your ECG and adjust as needed. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Buprenorphine and Artemether interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Buprenorphine and Artemether interaction managed?

What your care team may do: Avoid using these two together when a safer option exists. If both are truly needed, monitor your heart rhythm with an ECG and watch how well your buprenorphine is working. Stay cautious even after finishing the malaria treatment, because lumefantrine stays in the body for several days (about 3 to 6). Any buprenorphine dose change would be adjusted and individualized by… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Buprenorphine or Artemether need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: COARTEM® oral tablets, artemether lumefantrine oral tablets. Novartis Pharmaceuticals Corporation (per DailyMed), East Hanover, NJ, 2025. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.